Q2 2020

Filed Aug 14, 2020 · 10-Q · 45 days after period end · 0001493152-20-015885

Q2 2020 · 10-Q

Revenue—

Net Income

-$567.35K

N/M vs Q2 2019

EPS Diluted

-$0.06

N/M vs Q2 2019

Operating Income-$488,943N/M

Operating Cash Flowderived-$145,691N/M

Same quarter

Metric	Q2 2020	Q2 2019	Q2 2018	Q2 2017
Revenue	—	—	—	$0.00
Net Income	-$567.35K	-$278.51K	-$671.43K	-$451.09K
EPS Diluted	-$0.06	-$0.03	-$0.07	-$0.04

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protagenic Therapeutics, Inc.\new · CIK 1022899 · Engraved from SEC EDGAR